PMID: 7539473Jun 1, 1995Paper

Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS

The Journal of Infectious Diseases
A VecchiarelliF Bistoni

Abstract

The effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration on the functional status of polymorphonuclear leukocytes (PMNL) in neutropenic AIDS patients was investigated. PMNL destructive activity against Candida albicans or encapsulated or acapsular Cryptococcus neoformans was significantly impaired with respect to control subjects before rhG-CSF treatment. After subcutaneous administration of rhG-CSF (5 micrograms/kg), neutrophil counts increased 3- to 11-fold in 24 h and returned to baseline within 96 h. PMNL fungicidal activity showed significant enhancement 48-72 h after rhG-CSF administration that decreased to baseline within 96 h. Enhanced rhG-CSF-mediated destructive activity strictly correlated with augmented superoxide anion production by PMNL. These findings suggest that therapeutic use of rhG-CSF at appropriate schedules in neutropenic AIDS patients could decrease the risk of infection or, in association with antibiotic therapy, more rapidly resolve the occurring infections.

Citations

Jan 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J R GraybillT C Hardin
Jan 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B J Kullberg
Aug 28, 1998·Research in Immunology·B J Kullberg, E J Anaissie
Aug 28, 1998·Research in Immunology·S M Levitz
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A Casadevall, L A Pirofski
Dec 20, 1999·Journal of Hematotherapy & Stem Cell Research·D R Kuritzkes
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·E Farmaki, E Roilides
Aug 30, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E Roilides, E Farmaki
Jan 7, 2003·Infectious Disease Clinics of North America·Jose A Vazquez, Jack D Sobel
Aug 13, 2015·SpringerPlus·Mingshun ZhangMeiqing Shi
Dec 4, 2003·FEMS Immunology and Medical Microbiology·Tanja HeintelAndreas Meyerhans
May 16, 2006·FEMS Yeast Research·Claudia MonariAnna Vecchiarelli
Jan 1, 2019·PloS One·Abdu Kisekka MusubireUNKNOWN COAT and ASTRO trial teams
Jun 7, 2003·Transplant Infectious Disease : an Official Journal of the Transplantation Society·K PursellD Pitrak
Feb 3, 2007·Expert Review of Anti-infective Therapy·Jorge GarbinoEmmanuel Roilides
Aug 10, 2000·Clinical and Experimental Immunology·A VecchiarelliA Casadevall
Jan 16, 2021·Cellular and Molecular Life Sciences : CMLS·Ashley B Strickland, Meiqing Shi
Dec 1, 1995·Microbiological Reviews·R B Ashman, J M Papadimitriou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.